Septerna (NASDAQ:SEPN) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Septerna (NASDAQ:SEPN - Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $26.00 price objective on the stock. HC Wainwright also issued estimates for Septerna's Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.68 EPS, FY2025 earnings at $1.01 EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.46) EPS.

A number of other equities research analysts have also recently issued reports on the company. Wells Fargo & Company boosted their price objective on Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a report on Friday, May 16th. Cantor Fitzgerald upped their price objective on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, May 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Septerna currently has an average rating of "Moderate Buy" and a consensus price target of $26.75.

Septerna Price Performance

NASDAQ:SEPN traded up $0.14 on Monday, hitting $10.87. The company's stock had a trading volume of 395,273 shares, compared to its average volume of 692,457. Septerna has a one year low of $4.17 and a one year high of $28.99. The stock has a fifty day moving average of $8.75 and a two-hundred day moving average of $11.58.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The business had revenue of $0.22 million for the quarter. On average, analysts anticipate that Septerna will post -7.11 earnings per share for the current year.

Institutional Investors Weigh In On Septerna

A number of large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new stake in shares of Septerna during the 4th quarter valued at $25,000. New York State Common Retirement Fund bought a new position in Septerna in the fourth quarter valued at about $32,000. Legal & General Group Plc acquired a new position in Septerna during the fourth quarter worth about $42,000. Summit Investment Advisors Inc. bought a new position in shares of Septerna in the fourth quarter worth about $45,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Septerna during the 4th quarter valued at approximately $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.